

**Serveur Académique Lausannois SERVAL [serval.unil.ch](http://serval.unil.ch)**

## **Author Manuscript**

**Faculty of Biology and Medicine Publication**

**This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.**

Published in final edited form as:

**Title:** TAT-RasGAP317-326-mediated tumor cell death sensitization can occur independently of Bax and Bak.

**Authors:** Annibaldi A, Heulot M, Martinou JC, Widmann C

**Journal:** Apoptosis : an international journal on programmed cell death

**Year:** 2014 Apr

**Volume:** 19

**Issue:** 4

**Pages:** 719-33

**DOI:** 10.1007/s10495-013-0958-8

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

TAT-RasGAP<sub>317-326</sub>-mediated tumor cell death sensitization can occur  
independently of Bax and Bak

**Alessandro Annibaldi<sup>1\*</sup>, Mathieu Heulot<sup>1\*</sup>, Jean-Claude Martinou<sup>2</sup>, and  
Christian Widmann<sup>1</sup>**

<sup>1</sup>Department of Physiology, University of Lausanne, 1005 Lausanne, Switzerland;

<sup>2</sup>Department of Cell Biology, University of Geneva, Switzerland.

\* Equal contribution

Address correspondence: Christian Widmann, Department of Physiology, Rue du  
Bugnon 7, 1005 Lausanne, Switzerland, Phone: +41 21 692 5123, Fax: +41 21 692  
5505, E-mail: [Christian.Widmann@unil.ch](mailto:Christian.Widmann@unil.ch).

Short title: Bax activation favored by TAT-RasGAP<sub>317-326</sub>

Keywords: RasGAP; tumor sensitization; Bcl-2 family members; Bax

## Abstract

The increase of cancer specificity and efficacy of anti-tumoral agents are prime strategies to overcome the deleterious side effects associated with anti-cancer treatments. We described earlier a cell-permeable protease-resistant peptide derived from the p120 RasGAP protein, called TAT-RasGAP<sub>317-326</sub>, as being an efficient tumor-specific sensitizer to apoptosis induced by genotoxins *in vitro* and *in vivo*. Bcl-2 family members regulate the intrinsic apoptotic response and as such could be targeted by TAT-RasGAP<sub>317-326</sub>. Our results indicate that the RasGAP-derived peptide increases cisplatin-induced Bax activation. We found no evidence, using in particular knock-out cells, of an involvement of other Bcl-2 family proteins in the tumor-specific sensitization activity of TAT-RasGAP<sub>317-326</sub>. The absence of Bax and Bak in mouse embryonic fibroblasts (MEFs) rendered them resistant to cisplatin-induced apoptosis and consequently to the sensitizing action of the RasGAP-derived peptide. Surprisingly, in the HCT116 colon carcinoma cell line, the absence of Bax and Bak did not prevent cisplatin-induced apoptosis and the ability of TAT-RasGAP<sub>317-326</sub> to augment this response. Our study also revealed that p53, while required for an efficient genotoxin-induced apoptotic response, is dispensable for the ability of the RasGAP-derived peptide to augment the capacity of genotoxins to decrease long-term survival of cancer cells. Hence, even though genotoxin-induced Bax activity can be increased by TAT-RasGAP<sub>317-326</sub>, the sensitizing activity of the RasGAP-derived peptide can operate in the absence of a functional mitochondrial intrinsic death pathway.

## Introduction

The modulation of tumor cell sensitivity to genotoxic agents is one major issue in anticancer research <sup>1</sup>. The development of small molecules able to selectively increase the susceptibility of cancer cells to genotoxin-induced cell death would ameliorate the efficacy of chemotherapy and offer substantial benefits to individuals with cancer. A few compounds have been demonstrated to act as tumor sensitizers. These compounds are generally devoid, on their own, of any cytostatic or cytolytic effect on cells but they increase the ability of known anti-cancer agent to kill tumor cells. ADD70 corresponds to a fragment of the AIF (apoptosis-inducing factor) protein that binds the Hsp70 heat shock protein <sup>2</sup>. When expressed in colon carcinoma and lymphoma, ADD70 sensitizes them to cisplatin <sup>3</sup>. However, ADD70 does not have the ability to enter cells and cannot therefore be used as is as a tumor sensitizer *in vivo*. SmacN7 is a short 7 amino acid long peptide derived from Smac/Diablo, a protein released by the mitochondria in response to apoptotic stimuli that inhibits IAPs (inhibitor of apoptosis proteins) and hence favors the apoptotic process <sup>4</sup>. While apparently not inducing apoptosis of cancer cells by itself, a cell-permeable version of SmacN7 potentiates the action of genotoxins <sup>5-7</sup>.

Our laboratory has developed an anti-tumor peptide that selectively sensitizes several cancer cell lines, but not non-cancer cell lines, to genotoxin-induced apoptosis <sup>8</sup>. The anti-tumor activity of this peptide is carried by a ten-amino acid long sequence derived from the SH3 domain of p120 RasGAP. This sequence corresponds to residues 317-326 of the RasGAP protein <sup>8</sup>. The RasGAP<sub>317-326</sub> peptide was made cell permeable by hooking it to a short sequence of the HIV-TAT protein (residues 48 to 57) that allows polypeptides to penetrate cells <sup>9</sup>, resulting in the so-called TAT-RasGAP<sub>317-326</sub> peptide. This compound by itself, does not affect cell viability <sup>8</sup>. The RasGAP-derived peptide is also capable of increasing the anti-cancer activity of cisplatin and doxorubicin against human tumor xenografts <sup>10</sup> and to

augment the killing efficiency of photodynamic therapy in mesothelioma cells <sup>11</sup>. Recently, TAT-RasGAP<sub>317-326</sub> was shown to inhibit migration and invasion *in vitro*, indicating that it has the potential to function as an anti-metastatic compound <sup>12</sup>.

Genotoxins are DNA-damaging substances that exert their anti-tumor activity by causing apoptosis in cancer cells mainly through the mitochondrial pathway <sup>13-15</sup>. The genotoxin-induced DNA-damage response is orchestrated by a series of kinases (e.g. the ataxia-telangiectasia mutated, ATM) that sense the extent of the damage and activate downstream effectors <sup>16,17</sup>. One of the key DNA damage response effector is p53, a transcription factor that regulates the expression of genes involved in cell cycle arrest (e.g. p21) and apoptosis (e.g. Puma and Bax) <sup>18</sup>. Puma and Bax both belong to the Bcl-2 family member that tightly controls, directly or indirectly, the release of pro-apoptotic molecules from the mitochondria <sup>19</sup>. Members of this family share up to four BH (Bcl-2 Homology) domains and are conventionally subdivided into three groups on the basis of their pro- or anti-apoptotic activity and the BH domains they contain. Anti-apoptotic players (Bcl-2, Bcl-X<sub>L</sub>, Bcl-w, Mcl-1 and A1) and pro-apoptotic players (Bax, Bak and Bok) possess four BH domains, whereas the pro-apoptotic BH3-only proteins (Bid, Bim, Bad, Bmf; Bik, Noxa, Puma and Hrk) display only the BH3 domain <sup>20</sup>. When the balance between pro- and anti-apoptotic members of this family tips in favor of the former, mitochondrial membrane integrity is lost, cytochrome *c* is released in a Bax/Bak-dependent manner and this leads to caspase activation and apoptosis <sup>21</sup>. There are currently two main models describing how these proteins determine cell fate. These models are not necessarily mutually exclusive <sup>22-24</sup>. According to the ‘indirect model’, pro-apoptotic Bax and Bak are neutralized by anti-apoptotic proteins (e.g. Bcl-2) under normal conditions. When cells are subjected to apoptotic insults, BH3-only proteins displace Bax and Bak from their guardians allowing them to oligomerize in the outer mitochondria membrane, leading to cytochrome *c* release and cell death <sup>25</sup>. Conversely, the ‘direct model’ supports a

direct Bax/Bak activating role for a subgroup of the BH3-only members (tBid, Bim and Puma) called the ‘activators’. In basal conditions, these are sequestered by the anti-apoptotic proteins but in response to apoptotic stimuli they are displaced by the BH3-only ‘sensitizers’ members (e.g. Bad and Noxa). The freed ‘activators’ can then promote the oligomerization of Bax and Bak<sup>26,27</sup>.

We showed earlier that TAT-RasGAP<sub>317-326</sub> does not modulate MAPK signaling pathways (p38, ERK and JNK), NF-κB transcriptional activity or Akt protein levels and phosphorylation status<sup>28,29</sup>. Here we show that the activity of Bax can be modulated by TAT-RasGAP<sub>317-326</sub> in the context of tumor cells sensitization to genotoxin-induced apoptosis. Our data indicate however that Bcl-2 family members, including Bax and Bak, are dispensable for the capacity of the peptide to increase forms of deaths distinct from the classical mitochondrial apoptotic pathway.

## Materials and methods

### Chemicals

Cisplatin (Sigma, ref. n°P4394) was dissolved in water at a 1 mg/ml concentration and stored at -80°C. TNF $\alpha$  (Pierce, ref. n°RTNFA10) was dissolved in water at a concentration of 10  $\mu$ g/ml, aliquoted and stored at -80°C. Cycloheximide (Sigma, ref. n°C7698) was dissolved in methanol at 20mg/mL and stored at -20 °C. Paraformaldehyde (PFA) and HCl were from Acros (ref. n°30525-89-4 and 7647-01-0, respectively). Hoechst 33342 (Molecular Probe, Invitrogen, ref. n°H21492) was prepared as a 10 mg/ml water solution, stored at 4°C and used at a final concentration of 10  $\mu$ g/ml. The pan-caspase inhibitor MX1013 was a kind gift from Maxim Pharmaceuticals (San Diego, CA). Tris, sodium dodecyl sulfate (SDS), mannitol, sucrose and trichloroacetic acid were from Sigma (ref. n°T1503, L4390, M4125, S0389 and T9159 respectively). HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) was from AppliChem (ref. n°A3724). NaCl, EGTA (ethylenedis[oxymethylenetrinitrilo]tetraacetic acid) and bromophenol blue were from Acros (ref. n°7647-14-5, 67-42-5, and 115-39-9, respectively). CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) was from Fluka and AppliChem (ref. n°26680 and A1099.0050 respectively). EDTA (ethylenediaminetetraacetic acid), dithiothreitol (DTT), KCl and glycerol were from Fluka (ref. n°03620, 43817, 60130 and 49780, respectively). G-Sepharose beads were from GE Healthcare (ref. n°17-0618-01). Dynabeads Protein G was from Life Technologies (ref. n°10004D). Nitrocellulose membranes and gel filtration standard markers were from Biorad (ref. n°162-0115 and 151-1901 respectively). MgCl<sub>2</sub> was from Eurobio (ref. n°018023). EDTA-free Protease Inhibitor Cocktail Tablets were from Roche Applied Science (ref. n°1873580). Polyoxyethylene (20) sorbitan monolaurate (Tween 20) was from AppliChem (ref. n° 90005-64-5). SM-164 was synthesized as described <sup>30</sup>.

## Buffers

The composition of phosphate buffered saline (PBS) is 116 mM NaCl, 10.4 mM Na<sub>2</sub>HPO<sub>4</sub>, 3.2 mM KH<sub>2</sub>PO<sub>4</sub> (pH 7.4). The composition of the isotonic mitochondrial buffer (MB) is 10 mM HEPES (pH 7.4), 210 mM mannitol, 70 mM sucrose, 1 mM EDTA supplemented with one tablet of EDTA-free inhibitor (Roche) per 50 ml. The KCl buffer is made of 10 mM HEPES (pH 7.4), 125 mM KCl, 0.5 mM EGTA, 4 mM MgCl<sub>2</sub> and 5mM KHPO<sub>4</sub>. 1% CHAPS lysis buffer is made of 5 mM MgCl<sub>2</sub>, 137 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% CHAPS, 20 mM Tris-HCl, supplemented with one tablet of EDTA-free Protease Inhibitor Cocktail (Roche) per 50 ml. MonoQ-c buffer is made of 70 mM β-glycerophosphate, 0.5% Triton X-100, 2 mM MgCl<sub>2</sub>, 1 mM EGTA, 100 μM Na<sub>3</sub>VO<sub>4</sub>, 1 mM dithiothreitol, 20 μg/ml aprotinin supplemented with one tablet of complete EDTA-free Protease Inhibitor Cocktail per 50 ml. The composition of the elution buffer is 25 mM Hepes-NaOH pH7.5, 200mM NaCl, 1% CHAPS (W/V), 2mM DTT.

## Peptides

TAT and TAT-RasGAP<sub>317-326</sub> are retro-inverso peptides (i.e. synthesized with D-amino acids in the opposite direction compared to the natural sequence). The TAT moiety corresponds to amino acids 48-57 of the HIV TAT protein (RRRQRRKKRG) and the RasGAP<sub>317-326</sub> moiety corresponds to amino acids 317-326 of the human RasGAP protein (DTRLNTVWMW). These two moieties are separated by two glycine linker residues in the TAT-RasGAP<sub>317-326</sub> peptide. The peptides were synthesized at the Institute of Biochemistry, University of Lausanne, Switzerland, using Fmoc technology, purified by HPLC and tested by mass spectrometry.

## Cell lines



U2OS, HCT116 were cultured in DMEM (Invitrogen, ref. n°61965) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen, ref. n°10270-106) in 5% CO<sub>2</sub> at 37°C. HeLa cells were cultured in RPMI (Invitrogen, ref. n°61870) supplemented with 10% heat-inactivated FBS in 5% CO<sub>2</sub> at 37°C. Culturing of the cells prior to performing the experiments described in this article was performed in six-well plates by seeding 100'000 cells (Figure 1; Figure 5B), 150'000 (Figure 2, U2OS and HeLa cells), 200'000 (Figure 2, HCT116 cells), or 250'000 cells (Figure 5A; Figure 6) in the wells 24 hours before being treated as indicated in the figures. HeLa cells were infected with LeGo-iT2 empty and LeGO-iT2-Bcl-xL lentiviruses. Knock-out (KO) mouse embryonic fibroblast (MEFs) for Bcl-X<sub>L</sub>, Bcl-2, Mcl-1, Bim, Bmf and Bid were transformed by infecting them with a SV40 large T-encoding lentivirus<sup>31,32</sup>. KO MEFs for Bax, Bak, Bax/Bak and Bad were provided by the late Dr. Stanley Korsmeyer. Culturing of the KO MEFs prior to performing the experiments described in this article was performed during 24h in six-well plates by seeding 150'000 cells (Figure 4). For starvation, cells were washed three times with PBS and incubated for 24 hours with medium lacking FBS.

#### TRAIL-induced apoptosis

Cells were incubated for 24h with recombinant Flag-TRAIL and 2 µg/mL anti-FLAG M2 antibody diluted in culture medium.

#### UV illumination

Cells in culture dishes with the lid removed were UV-C- illuminated using the UV lamp of a cell culture hood (Fortuna from Scanlaf 1200) delivering an intensity of 0.25 J/m<sup>2</sup> per second. The cells were then incubated for the indicated periods of time in 5% CO<sub>2</sub> at 37°C.

### Apoptosis quantitation

Cells were fixed in 2% PFA and nuclei labeled with Hoechst 33342. Apoptotic cells (i.e. cells displaying a pycnotic nucleus) were counted under a Nikon Eclipse TS100 microscope. When apoptosis was assessed on a population of transfected cells, only green cells (i.e. cells having incorporated the transfected plasmids) were counted.

### Statistics

The statistical analyses were done with Microsoft Excel (XP edition) using the unpaired Student's t-test. Significance is indicated by an asterisk when  $P < 0.05/n$ , where P is the probability derived from the t test analysis and n is the number of comparisons done (Bonferroni correction). For Figures 4, 6, and 8, the statistical test used was one-way ANOVA followed by Bonferroni's post-hoc comparisons tests.

### Transfection

Cells were transfected using Lipofectamine 2000 (GibcoBRL, ref. n°18324-012) according to the manufacturer's instructions. Briefly, the indicated plasmids, together with 0.5 µg of GFP-encoding plasmid, were diluted in 250 µl DMEM without FBS. The amount of DNA used in the transfection was kept constant to 4 µg by adding the appropriate quantities of the pcDNA3 empty vector. In parallel, 8 µl of lipofectamine were added to 250 µl of DMEM without FBS and kept at room temperature for 5 minutes. Finally, the DNA-containing medium was added drop by drop to the lipofectamin-containing medium and the resulting 500 µl mix was added to cells. Five hours later, cells were washed once with fresh medium (DMEM supplemented with FBS) and cultured for an additional 20 hour period in the presence of the treatments indicated in the figures.

### Coimmunoprecipitation and immunoblotting

$7.5 \times 10^5$  U2OS and HeLa cells and  $10^6$  HCT116 cells were seeded in 10 cm plates and the next day treated as shown in the figures. Sixteen hours later, the cells were lysed in 300  $\mu$ l of 1% CHAPS lysis buffer and 700  $\mu$ g of the lysate proteins were immunoprecipitated overnight with 1.5  $\mu$ g of the 6A7 anti-Bax antibody (Figure 2). Immunoprecipitates were captured on 30  $\mu$ l of protein G-Sepharose at 4 °C for 2 hours. Immunocomplexes were then washed three times in CHAPS lysis buffer and eluted in 30  $\mu$ l of 2x sample buffer [25 mM Tris-HCl pH 7.5, 10% glycerol, 6% SDS, 0.02% of bromophenol blue and 100 mM freshly added DTT]. The immunoprecipitates and 50  $\mu$ g of total cell lysates were separated by SDS-PAGE and then transferred onto nitrocellulose membrane. The membranes were blocked with TBS (20 mM Tris, 130 mM NaCl, pH 7.6) containing 0.1% Tween 20 and 5% non-fat milk (TBS-TM) and incubated overnight at 4°C with a 1:1000 dilution of the N-20 anti-Bax antibody (Figure 2) or 1:1000 dilutions of the antibodies directed at the proteins indicated in the other figures. Blots were then washed with TBS containing 0.1% Tween 20 (TBS-T), incubated 1 hour at room temperature with the appropriate fluorophore-conjugated secondary antibody (1:5000 dilution) and subsequently visualized with the Odyssey infrared imaging system (LICOR Biosciences, Bad Homburg, Germany). Bak immunoprecipitation was performed as described above with the following modifications: 2000  $\mu$ g of the lysate proteins were immunoprecipitated overnight with 1.5  $\mu$ g of the Ab-2 anti-Bak antibody (Figure 2E). Immunoprecipitates were captured with 15  $\mu$ l of Dynabeads Protein G.

### Crosslinking of mitochondrial proteins

HeLa cells were harvested in PBS and centrifuged 10min at 1000 g. Cells were then resuspended in isotonic mitochondrial buffer (MB), broken by five passages through a 25G1 0.5- by 2.5 mm needle fitted on a 2 ml syringe and centrifuged at 1500 g for 5 min. This

procedure was repeated twice and supernatants from each step were pooled and centrifuged 5 min at 1500 g. Supernatant was collected, centrifuged 5min at 2000 g and further centrifuged 10 min at 9000 g. Pellet was resuspended in MB (100  $\mu$ L) and centrifuged 10min at 7000 g and the pellet, representing the mitochondrial fraction, was finally resuspended in MB. Mitochondria (40  $\mu$ g) were incubated for 30 min at room temperature with DSS 5 mM. The reaction was stop by addition of 1 M Tris-HCl pH 8 quenching buffer. Mitochondria were centrifuged, resuspended in Ripa lysis buffer and incubated on ice for 15 min. After centrifugation at maximum speed, the supernatant was collected, mixed with loading buffer and analyzed by western blot using anti-Bax antibody.

#### Western blotting

Cells were lysed in 100  $\mu$ l of monoQ-c buffer. Visualization of the bands was performed using the Odyssey infrared imaging device and software (Licor, Homburg, Germany). Protein levels were quantitated using ImageJ software.

#### Antibodies

The anti-Puma rabbit polyclonal IgG antibody, the anti-Bid rabbit polyclonal antibody, the anti-Bcl-X<sub>L</sub> rabbit polyclonal IgG antibody, and the anti-caspase-3 rabbit polyclonal IgG antibody were from Cell Signaling (ref. n°4976, 2002, 2764 and 9665, respectively). The 6A7 anti-active Bax mouse monoclonal IgG1, the N-20 anti-total Bax rabbit polyclonal IgG, and the G23 anti-total Bak rabbit polyclonal IgG antibodies were from SantaCruz (ref. n°sc-23959, n°sc-493 and n°sc-832 respectively). The anti-Bcl-2 mouse monoclonal IgG1 antibody was from Upstate (ref. n°05-341), the Y37 anti-Mcl-1 rabbit monoclonal IgG antibody was from Abcam (ref. n°ab32087), the 3C5 anti-Bim rat monoclonal IgG2a antibody and the 1E1-1-10 anti-cIAP1 rat monoclonal IgG2a antibody were from Enzo Life Sciences (ref. n°ALX-

804-527-C100 and n°ALX-803-335-C100, respectively). The 48/hILP/XIAP anti-XIAP mouse monoclonal IgG1 antibody was from BD Biosciences (ref. n°610762). The Ab-2 anti-active Bak mouse monoclonal IgG2b antibody was from Merck (ref. n°AM04). The mouse monoclonal anti-FLAG M2 antibody was from Sigma (ref. n° F1804). Secondary antibodies were goat anti-mouse IRDye800-conjugated antibody (Rockland, ref. n°610-132-121), goat anti-rabbit Alexa Fluor 680-conjugated antibody (Molecular Probes, ref. n°A21109) and donkey anti-rabbit HRP-conjugated antibody (Jackson ImmunoResearch, ref. n° 711-035-152).

#### Plasmids

The **pcDNA3** expression vector is from Invitrogen. **pEGFP-C1** (Clontech) encodes the green fluorescent protein. **Puma.cmv** (Origene) encodes human Puma. hTPP53.dn3 encodes the human p53. It was generated by subcloning the 1900 bp EcoRI/BamHI fragment from hTP53.lti (gift from Richard Iggo) into pcDNA3 opened with the same two enzymes. **TRIP-PGK-IRESNEO-WHV** (#350) is a lentiviral vector bearing the neomycine resistance. **SV40LargeTantigen.pBABE-puro** (#731) encodes the SV40 large T antigen (Addgene; plasmid 13970). **SV40LargeTantigen.lti-neo** (#738) similarly encodes the large T antigen but in a lentiviral expression vector. It was constructed by subcloning the BamHI 2187 base pairs fragment of SV40LargeTantigen.pBABE-puro into TRIP-PGK-IRESNEO-WHV opened with the same enzyme. **LeGO-iT2-Bcl-xL** (#821) was constructed by subcloning the 770 bp EcoRI fragment from hBcl-xL.dna (#274) in into LeGO-iT2 (Addgene: plasmid 27343). The extension .lti indicates that the backbone is a lentiviral vector. The extension .cmv indicates that the backbone is the pCMV-AC vector. The extension .dn3 indicates that the backbone plasmid is pcDNA3.

## Results

### **TAT-RasGAP<sub>317-326</sub> sensitizes diverse cancer cells to genotoxin-induced apoptosis but not to TNF $\alpha$ -induced apoptosis and variably to starvation- and UV-induced apoptosis**

We demonstrated earlier that TAT-RasGAP<sub>317-326</sub> sensitizes various cancer cell lines to apoptosis induced by genotoxins such as cisplatin and doxorubicin<sup>8</sup>. These compounds induce apoptosis via the intrinsic apoptosis pathway<sup>13,14</sup>. To gain further insight about the manner by which TAT-RasGAP<sub>317-326</sub> exerts its tumor sensitization effect, HeLa, U2OS, and HCT116 cancer cells were treated with additional pro-apoptotic compounds, including TNF $\alpha$  that induces cell death via the extrinsic apoptotic pathway. Figure 1A shows that TAT-RasGAP<sub>317-326</sub> favored cisplatin-induced apoptosis in the three different cancer cell lines, confirming earlier results<sup>8,33</sup>. TAT-RasGAP<sub>317-326</sub> sensitized some, but not all, tumor cell lines to UV- or growth factor deprivation-induced apoptosis, despite the fact that these treatments can activate the intrinsic apoptotic pathway<sup>34,35</sup>. None of the tumor cell lines was sensitized by the peptide to TNF $\alpha$ , an extrinsic pathway stimulator<sup>36,37</sup> in presence of cycloheximide (CHX), a protein synthesis inhibitor that prevents the expression of anti-apoptotic proteins that would otherwise counteract the pro-apoptotic abilities of TNF $\alpha$ <sup>38,39</sup>. These results suggest that TAT-RasGAP<sub>317-326</sub> exerts a pro-apoptotic role in conditions where the intrinsic cell death pathway is engaged. However since HeLa and HCT116 are type II cells<sup>40,41</sup> (see also Figure 1B), i.e. they need the mitochondrial pathway to fully activate caspase-3 in response to extrinsic death stimuli<sup>42</sup>, it is unclear why TAT-RasGAP<sub>317-326</sub> does not have any sensitizing effect on these cell lines when incubated with TNF $\alpha$ . One possibility is that CHX prevents the expression of protein that is targeted by TAT-RasGAP<sub>317-326</sub> to mediate its sensitization effect. To test this hypothesis, we used another extrinsic pathway stimulator, TNF-related apoptosis-inducing ligand (TRAIL)<sup>43</sup>. Unlike TNF $\alpha$  + CHX, the apoptotic response induced by TRAIL was increased by TAT-RasGAP<sub>317-326</sub> in HeLa cells

(Figure 1B). These cells were confirmed to be type II cells by the complete protection against TRAIL-induced apoptosis conferred by Bcl-X<sub>L</sub> over-expression (Figure 1C).

### **TAT-RasGAP<sub>317-326</sub> increases cisplatin-induced Bax activation**

Tumor cells sensitized by TAT-RasGAP<sub>317-326</sub> to genotoxin-induced apoptosis show increased caspase-3 activation and more pronounced mitochondrial membrane depolarization<sup>33</sup>. This suggests that the RasGAP-derived peptide acts upstream of cytochrome *c* release from mitochondria. Consequently, Bax, which is required for mitochondrial outer membrane permeabilization, cytochrome *c* release, and caspase activation<sup>21</sup>, should be more activated by genotoxins in the presence of TAT-RasGAP<sub>317-326</sub>. To study the status of Bax activation, we performed immunoprecipitation experiments with an antibody (Bax 6A7) that only binds the active conformation of Bax. Figure 2A shows that while TAT-RasGAP<sub>317-326</sub> alone does not affect Bax activation, it increases cisplatin-induced Bax stimulation. Consistent with these observations, the peptide did not induce Bax oligomerization by itself but amplified cisplatin-induced Bax oligomerization (Figure 2B). Figure 2A (lower blots) shows that neither cisplatin nor TAT-RasGAP<sub>317-326</sub>, alone or in combination, alter total Bax cellular levels. However, the amount of Bax associated with the mitochondria, either as monomers or dimers, is increased in cells treated with cisplatin and TAT-RasGAP<sub>317-326</sub> compared to cells treated with cisplatin alone (Figure 2B). It appears thus that the RasGAP-derived peptide can facilitate cisplatin-mediated Bax recruitment to the mitochondria.

There is evidence that caspase activation induces a positive feedback loop to increase Bax activation and cytochrome *c* release from the mitochondria<sup>44</sup>. To determine if TAT-RasGAP<sub>317-326</sub> modulates this feedback loop, the experiment shown in Figure 2A was repeated in the presence of the MX1013 pan-caspase inhibitor<sup>45,46</sup> that efficiently blocks executioner caspase activity (Figure 2C). Figure 2D shows that caspase inhibition does not

prevent TAT-RasGAP<sub>317-326</sub> from enhancing cisplatin-mediated Bax activation. The role of Bak, the other Bcl-2 family member involved in mitochondrial permeabilization was also investigated but we did not observe modulation of cisplatin-induced Bak activation by TAT-RasGAP<sub>317-326</sub> (Figure 2E). As Bak can substitute for Bax in rendering tumor cells more sensitive to cisplatin in the presence of the RasGAP-derived peptide (see below), we currently cannot provide an explanation for this observation.

### **TAT-RasGAP<sub>317-326</sub> does not modulate Bcl-2 and IAP family members**

Bax activation is controlled by pro- and anti-apoptotic members of the Bcl-2 family of proteins<sup>19,21</sup>. Conceivably, TAT-RasGAP<sub>317-326</sub> could favor genotoxin-induced apoptosis by increasing the levels of pro-apoptotic Bcl-2 family members and/or decreasing the levels of the anti-apoptotic members. However, the peptide did neither modulate the expression of pro-apoptotic Bim, Puma and Bid proteins nor the anti-apoptotic Bcl-X<sub>L</sub>, Bcl-2 and Mcl-1 proteins (Figure 3). Another possibility that could explain how TAT-RasGAP<sub>317-326</sub> favors apoptosis is inhibition of inhibitor of apoptosis (IAP) family proteins. However, the peptide did not alter cellular levels of cIAP1, cIAP2 and XIAP (Figure 3). Therefore, modulation of the expression of IAPs and Bcl-2 family members is not the mechanism used by TAT-RasGAP<sub>317-326</sub> to favor Bax activation and apoptosis. However, this does not exclude the possibility that the peptide affects the activity of these proteins.

### **Targeted disruption of individual Bcl-2 family members or IAPs does not prevent TAT-RasGAP<sub>317-326</sub>-mediated tumor cell sensitization**

Large T antigen-transformed MEFs lacking specific Bcl-2 family member were used to investigate the role of this protein family in the capacity of TAT-RasGAP<sub>317-326</sub> to sensitize tumor cells to genotoxin-induced apoptosis. MEFs are not cancer cells and hence are not susceptible to TAT-RasGAP<sub>317-326</sub>-mediated genotoxin sensitization. However, transforming



MEFs with the SV40 large T antigen renders them sensitive to the peptide<sup>31</sup>. Figure 4A shows that transformed MEFs lacking the pro-apoptotic BH3-only Bid, Bim, Bmf, or Bad proteins or the anti-apoptotic Bcl-X<sub>L</sub>, Bcl-2, or Mcl-1 proteins were efficiently sensitized by TAT-RasGAP<sub>317-326</sub> to cisplatin-induced apoptosis. Furthermore, the pro-apoptotic family members Bax and Bak, crucial for outer mitochondrial membrane permeabilization are not individually required to mediate TAT-RasGAP<sub>317-326</sub> sensitization. As expected<sup>47</sup>, transformed MEFs lacking both Bax and Bak were totally resistant to cisplatin-induced death. We next examined the implication of cIAP1/2 and XIAP in TAT-RasGAP<sub>317-326</sub> sensitization to cisplatin-induced apoptosis. We used the SM-164 Smac mimetic to induce cIAP1/2 degradation and XIAP inhibition<sup>48</sup>. In presence of the Smac mimetic, the sensitization to cisplatin induced by the peptide was not altered, despite strong reduction in cIAP1 and cIAP2 levels, indicating that cIAP1/2 and XIAP are not involved in TAT-RasGAP<sub>317-326</sub>-mediated sensitization of cisplatin-induced apoptosis.

### **TAT-RasGAP<sub>317-326</sub> does not sensitize cells to Puma over-expression**

We previously hypothesized that an intact p53/Puma axis was required for efficient genotoxin-induced apoptosis and for TAT-RasGAP<sub>317-326</sub> to favor genotoxin-induced apoptosis in cancer cells<sup>33</sup>. We reasoned that if Puma is necessary and sufficient for the sensitizing activity of the RasGAP-derived peptide, ectopic expression of Puma should render tumor cells sensitive to TAT-RasGAP<sub>317-326</sub> in the absence of cisplatin. Figure 5A shows that transfecting U2OS cells with amounts of Puma-encoding plasmids in the 0.5 to 3.5 µg range (open circles) led to similar levels of Puma expression than obtained by treating the cells with concentrations of cisplatin in the 2.5 to 30 µM range (closed squares). However, TAT-RasGAP<sub>317-326</sub> only sensitized cells incubated with cisplatin and not those transfected with the Puma-encoding plasmids (Figure 5B).

Puma is a p53 transcription target that may, once synthesized, need p53 to exert its full pro-apoptotic actions<sup>49</sup>. Figure 6 shows that ectopic expression of p53 in U2OS cells induced apoptosis. However this was neither modulated by Puma nor by TAT-RasGAP<sub>317-326</sub>. Taken together these data suggest that TAT-RasGAP<sub>317-326</sub> does not directly amplify the DNA-damage-induced p53/Puma arm. Hence, even though cisplatin requires p53 and Puma to induce apoptosis<sup>33</sup>, this genotoxin may modulate other pro-apoptotic signals that are targeted by TAT-RasGAP<sub>317-326</sub> to induce cell death in cancer cells.

### **TAT-RasGAP<sub>317-326</sub> affects long term survival of cancer cells independently of p53**

The above observation that the RasGAP-derived peptide does not amplify the p53/Puma axis led us to reconsider the implication of p53 in the TAT-RasGAP<sub>317-326</sub>-mediated sensitization of cancer cells. Cells lacking an intact p53/Puma axis show a drastically reduced apoptotic rate when exposed to genotoxin treatment<sup>33</sup>, but they may remain sensitive to the drugs on longer term exposure. Indeed, Figure 7 shows that the survival of either p53-positive or p53-negative HCT116 cells, tested by colony formation assay, was reduced by cisplatin treatment to similar extent. Importantly, TAT-RasGAP<sub>317-326</sub> significantly augmented cisplatin-mediated cell survival impairment in both cases (Figure 7). It was suggested, based on earlier observation that the HCT116 tumor cell line lacking either p53 or Puma did not undergo more cisplatin-induced apoptosis in the presence of TAT-RasGAP<sub>317-326</sub><sup>33</sup>, that TAT-RasGAP<sub>317-326</sub> required a functional p53-Puma axis to exert its sensitizing function. The data presented in Figure 7 demonstrate that this initial assumption is not correct. Presumably, the absence of p53 or Puma by dramatically increasing the resistance of HCT116 cells to cisplatin-induced apoptosis<sup>33</sup> masks the sensitizing effect of the peptide in short-term experiments. Another difference to take into account is the method used to evaluate the sensitization to cisplatin. In previous report, sensitization was evaluated using apoptosis-specific assays (i.e. scoring cells

with pycnotic nuclei). Here, HCT116 p53 KO cells were shown to be sensitized to cisplatin using colony formation assays. Apoptosis can affect the ability of cells to form colonies but other forms of death (e.g. mitotic catastrophe, necrosis) can too. Hence the results shown in Figure 7 indicate that TAT-RasGAP<sub>317-326</sub> might sensitize tumors to several types of cell death.

### **TAT-RasGAP<sub>317-326</sub> sensitizes HCT116 cells irrespectively of their Bax and Bak status**

Recently, HCT116 cell lines lacking Bax and/or Bak were generated<sup>50</sup>. We aimed to determine if Bax and Bak were required for cisplatin-induced death and TAT-RasGAP<sub>317-326</sub>-mediated sensitization in the HCT116 background as they were in the MEF background (see Figure 4). Bax and Bak status in HCT116 wild-type, single KOs and double KO was first confirmed by Western blotting (Figure 8A). In contrast to MEFs, the absence of Bax and Bak in HCT116 cells reduced, but did not abrogate the ability of cisplatin to induce apoptosis (Figure 8B) and, importantly, did not prevent TAT-RasGAP<sub>317-326</sub> from sensitizing these cells to cisplatin-induced apoptosis. Using colony-formation assays, it was found that cisplatin reduced more or less to similar extents the survival of HCT116 cells expressing or not Bax and Bak (Figure 8C). The absence of Bax and Bak did not alter the capacity of TAT-RasGAP<sub>317-326</sub> to favor cisplatin-mediated survival decrease. These results indicate that apoptosis and cell death induced by genotoxins such as cisplatin can occur in the absence of a functional mitochondrial apoptotic pathway (i.e. in the absence of Bax and Bak in HCT116 cells) and that these modes of death can be augmented by TAT-RasGAP<sub>317-326</sub>.

## Discussion

This study provides advances in the understanding on the mode of action of TAT-RasGAP<sub>317-326</sub>. It shows that this peptide enhances cisplatin-induced Bax activation. The RasGAP-derived peptide can therefore positively modulate the intrinsic apoptotic pathway activated by genotoxins. But the ability of TAT-RasGAP<sub>317-326</sub> to favor genotoxin-induced tumor cell death is not limited to the intrinsic apoptotic pathway because cisplatin-induced apoptosis and TAT-RasGAP<sub>317-326</sub>-mediated sensitization can occur in cells lacking Bax and Bak and because tumor cells lacking p53 can be sensitized by the RasGAP-derived peptide to die by an apparently non-apoptotic form of cell death. Hence, TAT-RasGAP<sub>317-326</sub>-mediated tumor cell sensitization to genotoxins can occur independently of Bax, Bak, and p53 through a death pathway that remains to be clarified.

### *Increased Bax stimulation in the context of TAT-RasGAP<sub>317-326</sub>-mediated sensitization*

Bax and Bak are Bcl-2 family members the activation and oligomerization of which induce permeabilization of the mitochondrial outer membrane, resulting in the release of cytochrome *c*<sup>21</sup>. This study shows that TAT-RasGAP<sub>317-326</sub> increases genotoxin-induced Bax activation. However, how this augmentation is accomplished remains unclear. First, the ability of TAT-RasGAP<sub>317-326</sub> to increase genotoxin-induced Bax activation did not require caspase activation (Figure 2). Therefore, the peptide does not amplify a positive feedback loop on Bax activation induced by the activation of caspases following cytochrome *c* release<sup>44</sup>. Second, Bax activation does not result from a peptide-induced balance shift between the expression levels of pro- and anti-apoptotic Bcl-2 family members. Indeed, the protein levels of Bcl-2, Bcl-X<sub>L</sub>, Mcl-1, Bim, Puma, and Bid were not modulated by TAT-RasGAP<sub>317-326</sub> (Figure 3). Moreover, the expression of IAPs was not modified by RasGAP-derived peptide. However, this does not exclude the possibility that the peptide affects the activity of these proteins. In

addition, all the Bcl-2 family proteins we have tested (Bcl-2, Bcl-X<sub>L</sub>, Mcl-1, Bim, Bid, Bmf and Bad) were shown to be individually dispensable for the sensitizing activity of the peptide. This suggests that these proteins are not direct or indirect targets of TAT-RasGAP<sub>317-326</sub>. However, the possibility that the RasGAP-derived peptide targets several Bcl-2 family members, which compensate each other when one is absent to mediate the sensitizing action of the peptide, cannot be excluded at the present time. Furthermore, HCT116 Bax KO cells were found to be sensitized to genotoxin-induced death. This indicates that TAT-RasGAP<sub>317-326</sub> sensitization is not strictly restricted to increased Bax activation.

#### ***TAT-RasGAP<sub>317-326</sub>-mediated sensitization independently of Bax and Bak (and p53)***

In contrast to MEFs, HCT116 cells lacking Bax and Bak can still undergo genotoxin-induced apoptosis and this cell death response can be increased by TAT-RasGAP<sub>317-326</sub>. Moreover, HCT116 cells lacking p53, despite being greatly compromised in their ability to apoptose in response to genotoxins, as evidenced by their resistance to pycnosis, are nevertheless more efficiently killed in long-term survival experiments (colony-formation assays) by genotoxins when incubated with the RasGAP-derived peptide. Thus, TAT-RasGAP<sub>317-326</sub> has the capacity to favor non-mitochondrial forms of cell death.

Recent findings in non-small-cell lung cancer showed that Bax and Bak are dispensable for cisplatin-induced apoptosis<sup>51</sup>. In this study, using cisplatin-sensitive and cisplatin-resistant cell lines lacking Bax and Bak, it was shown that cisplatin-induced apoptosis may rely on caspase-8 activation in an acid sphingomyelinase and FADD-dependent manner. Incidentally, it is also noticed that Bax/Bak DKO MEFs were found to be totally resistant to cisplatin-induced apoptosis in line of the data presented in Figure 4. One could hypothesize that apoptosis in Bax/Bak DKO HCT116 cells is mediated through caspase-8 activation and that

TAT-RasGAP<sub>317-326</sub> increases this response. The implication of caspase-8 in TAT-RasGAP<sub>317-326</sub> cancer cell sensitization remains to be defined however.

The present report also clarifies the role played by p53 (and Puma) in TAT-RasGAP<sub>317-326</sub>-mediated sensitization of tumor cells to genotoxin-induced apoptosis. Interpretations of earlier work were that TAT-RasGAP<sub>317-326</sub> required a functional p53-Puma axis to favor apoptosis of cisplatin-stimulated tumor cells<sup>33</sup>. We therefore hypothesized that reproducing expression of p53 and Puma in cancer cells, which occurs when cells are treated with cisplatin, would render them sensitive to TAT-RasGAP<sub>317-326</sub>. However, this proved not to be the case (Figure 5 and 7). Moreover, tumor cells lacking p53, even though highly resistant to cisplatin-induced apoptosis in short-term experiments<sup>33</sup>, were nevertheless less able to survive long-term cisplatin treatment when co-treated with TAT-RasGAP<sub>317-326</sub> (Figure 7). This indicates that the RasGAP-derived peptide does not require p53 to exert its tumor sensitization activity. Hence, p53 and Puma are not targets of TAT-RasGAP<sub>317-326</sub>. The apparent requirement of p53 and Puma for the genotoxin-sensitizing function of the peptide in short-term apoptosis assays most likely results from the fact that genotoxins inefficiently induce apoptosis of tumor cells lacking a functional p53-Puma axis<sup>52</sup>. In other words, the absence of TAT-RasGAP<sub>317-326</sub>-mediated sensitization observed in p53- or Puma-negative cells merely reflects the fact these cells cannot properly undergo genotoxin-induced apoptosis. Measuring cell death in short-term assays (e.g. within the first 24 hours of treatment) might lead to an underestimation of the killing potential of genotoxins, as long-term cell survival is not taken into account. This may particularly be the case in cells bearing mutations in apoptosis-controlling proteins. Tumor cells lacking p53 can bypass the primary apoptotic decision, which takes place shortly after the administration of an apoptotic stimulus, and undergo several cell divisions before dying. This can occur either by p53-independent apoptosis or as a result of mitotic catastrophe or necrotic cell death<sup>53</sup>. The observation that TAT-RasGAP<sub>317-326</sub>, in combination with

cisplatin, reduces the viability of p53-negative tumor cells demonstrates that this peptide can also positively reinforces p53-independent cell death mechanism(s) that occur in a more delayed manner compared to short-term apoptosis.

Earlier reports indicate that cisplatin <sup>51</sup> and TRAIL (reviewed in <sup>54</sup>) induce caspase-8 activation. Since the present work shows that TAT-RasGAP<sub>317-326</sub> sensitizes tumor cells to cisplatin and TRAIL-induced apoptosis, it raises the possibility that the peptide acts at the level of caspase-8 or of a caspase 8-containing complex. The activation of caspase-8 is modulated by several proteins, for instance positively by Fas-associated death domain protein (FADD) and negatively by FADD-like interleukin-1 $\beta$ -converting enzyme (FLICE)-inhibitory (cFLIP) <sup>55</sup>. Hypothetically, TAT-RasGAP<sub>317-326</sub> could favor FADD activity to activate caspase-8 or the peptide could neutralize the cFLIP inhibitory effect. Further work is now needed to dissect the role played by caspase-8 and its binding partners in the tumor sensitizing activities of TAT-RasGAP<sub>317-326</sub>.

## **Acknowledgements**

We thank Dr. Pascal Meier (Institute of Cancer Research: Royal Cancer Hospital, London, UK) for the generous gift of IAP-specific antibodies; Dr. David Huang (Walter and Eliza Hall Institute of Medical Research, Parkville Victoria, Australia) for providing MEFs lacking specific Bcl-2 family members; Dr. Richard J. Youle (Biochemistry Section, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA) for HCT116 Bak and HCT116 Bax Bak DKO and Dr. Pascal Schneider (University of Lausanne, Département de Biochimie, Lausanne, Switzerland) for Flag-TRAIL.

## **Conflict of interest**

CW is a coinventor of the TAT-RasGAP<sub>317-326</sub> compound as a genotoxin sensitizer (patent owned by the University of Lausanne) and may receive royalties from patent licensing if the compound is commercialized. Patent numbers and dates are WO 2005000887 (30.6.2003) and WO 2010097720 (30.1.2009). The other authors declare that they have no conflict of interest. This work was supported by Swiss National Science Foundation grant 31003A\_141242 (to CW). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.



## References

1. Michod D, Widmann C. DNA-damage sensitizers: potential new therapeutical tools to improve chemotherapy. *Crit Rev.Oncol.Hematol.* 2007; 63: 160-171.
2. Schmitt E, Parcellier A, Gurbuxani S *et al.* Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant. *Cancer Research* 2003; 63: 8233-8240.
3. Schmitt E, Maingret L, Puig PE *et al.* Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. *Cancer Research* 2006; 66: 4191-4197.
4. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. *Nat Rev Mol Cell Biol* 2008; 9: 231-241.
5. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/T. *Nat.Med.* 2002; 8: 808-815.
6. Yang L, Mashima T, Sato S *et al.* Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. *Cancer Research* 2003; 63: 831-837.
7. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNF $\alpha$ -mediated cell death. *Science* 2004; 305: 1471-1474.

8. Michod D, Yang JY, Chen J, Bonny C, Widmann C. A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells. *Oncogene* 2004; 23: 8971-8978.
9. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. *Br.J.Pharmacol.* 2009; 157: 195-206.
10. Michod D, Annibaldi A, Schaefer S, Dapples C, Rochat B, Widmann C. Effect of RasGAP N2 fragment-derived peptide on tumor growth in mice. *J.Natl.Cancer Inst.* 2009; 101: 828-832.
11. Pittet O, Petermann D, Michod D *et al.* Effect of the TAT-RasGAP<sub>317-326</sub> peptide on apoptosis of human malignant mesothelioma cells and fibroblasts exposed to *meso*-tetra-hydroxyphenyl-chlorin and light. *J.Photochem.Photobiol.B* 2007; 88: 29-35.
12. Barras D, Lorusso G, Ruegg C, Widmann C. Inhibition of cell migration and invasion mediated by the TAT-RasGAP<sub>317-326</sub> peptide requires the DLC tumor suppressor. *Oncogene* 2013; doi:10.1038/onc.2013.465.
13. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. *Oncogene* 2002; 21: 8786-8803.
14. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. *Experimental Cell Research* 2000; 256: 42-49.
15. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. *Oncogene* 2006; 25: 4798-4811.
16. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. *Nat.Rev.Cancer* 2004; 4: 216-225.

17. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. *Nat.Rev.Cancer* 2003; 3: 155-168.
18. Michalak E, Villunger A, Erlacher M, Strasser A. Death squads enlisted by the tumour suppressor p53. *Biochem.Biophys.Res.Commun.* 2005; 331: 786-798.
19. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. *Nature Reviews Molecular Cell Biology* 2008; 9: 47-59.
20. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. *Science* 2004; 305: 626-629.
21. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? *Trends in Cell Biology* 2008; 18: 157-164.
22. Galonek HL, Hardwick JM. Upgrading the BCL-2 network. *Nat.Cell Biol.* 2006; 8: 1317-1319.
23. Chen C, Cui J, Zhang W, Shen P. Robustness analysis identifies the plausible model of the Bcl-2 apoptotic switch. *FEBS.Lett.* 2007; 581: 5143-5150.
24. Villunger A, Labi V, Bouillet P, Adams J, Strasser A. Can the analysis of BH3-only protein knockout mice clarify the issue of 'direct versus indirect' activation of Bax and Bak? *Cell Death & Differentiation* 2011; 18: 1545-1546.
25. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. *Current Opinion in Cell Biology* 2005; 17: 617-625.
26. Giam M, Huang DC, Bouillet P. BH3-only proteins and their roles in programmed cell death. *Oncogene* 2008; 27 Suppl 1: S128-S136.

27. Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. *Dev.Cell* 2011; 21: 92-101.
28. Michod D, Widmann C. TAT-RasGAP<sub>317-326</sub> requires p53 and PUMA to sensitize tumor cells to genotoxins. *Mol.Cancer Res.* 2007; 5: 497-507.
29. Michod D, Yang JY, Chen J, Bonny C, Widmann C. A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells. *Oncogene* 2004; 23: 8971-8978.
30. Sun H, Nikolovska-Coleska Z, Lu J *et al.* Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. *J.Am.Chem.Soc.* 2007; 129: 15279-15294.
31. Annibaldi A, Dousse A, Martin S, Tazi J, Widmann C. Revisiting G3BP1 as a RasGAP binding protein: sensitization of tumor cells to chemotherapy by the RasGAP 3127-326 sequence does not involve G3BP1. *PLoS One* 2011; 6: e29024.
32. Chen L, Willis SN, Wei A *et al.* Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. *Molecular Cell* 2005; 17: 393-403.
33. Michod D, Widmann C. TAT-RasGAP<sub>317-326</sub> requires p53 and PUMA to sensitize tumor cells to genotoxins. *Mol.Cancer Res.* 2007; 5: 497-507.
34. Bialik S, Cryns VL, Drincic A *et al.* The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. *Circ.Res.* 1999; 85: 403-414.

35. Dunkern TR, Fritz G, Kaina B. Ultraviolet light-induced DNA damage triggers apoptosis in nucleotide excision repair-deficient cells via Bcl-2 decline and caspase-3/-8 activation. *Oncogene* 2001; 20: 6026-6038.
36. Hengartner MO. The biochemistry of apoptosis. *Nature* 2000; 407: 770-776.
37. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. *Experimental Cell Research* 2000; 256: 58-66.
38. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. *Immunity* 2004; 21: 461-465.
39. Lavrik I, Golks A, Krammer PH. Death receptor signaling. *Journal of Cell Science* 2005; 118: 265-267.
40. Ozoren N, El-Deiry WS. Defining characteristics of types I and II apoptotic cells in response to TRAIL. *Neoplasia*. 2002; 4: 551-557.
41. Mandal M, Maggirwar SB, Sharma N, Kaufmann SH, Sun SC, Kumar R. Bcl-2 prevents CD95 (Fas/APO-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase and restores the NF-kappaB signaling pathway. *Journal of Biological Chemistry* 1996; 271: 30354-30359.
42. Scaffidi C, Fulda S, Srinivasan A *et al.* Two CD95 (APO-1/Fas) signaling pathways. *EMBO Journal* 1998; 17: 1675-1687.
43. Wiley SR, Schooley K, Smolak PJ *et al.* Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity* 1995; 3: 673-682.

44. Lakhani SA, Masud A, Kuida K *et al.* Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. *Science* 2006; 311: 847-851.
45. Jaeschke H, Farhood A, Cai SX, Tseng BY, Bajt ML. Protection against TNF-induced liver parenchymal cell apoptosis during endotoxemia by a novel caspase inhibitor in mice. *Toxicol.Appl.Pharmacol.* 2000; 169: 77-83.
46. Yang W, Guastella J, Huang JC *et al.* MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity. *Br.J.Pharmacol.* 2003; 140: 402-412.
47. Wei MC, Zong WX, Cheng EH *et al.* Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. *Science* 2001; 292: 727-730.
48. Lu J, Bai L, Sun H *et al.* SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. *Cancer Research* 2008; 68: 9384-9393.
49. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. *Science* 2005; 309: 1732-1735.
50. Wang C, Youle RJ. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak. *Oncogene.* 2012; 31: 3177-3189.
51. Paul I, Chacko AD, Stasik I *et al.* Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. *Cell Death.Dis.* 2012; 3: e449.
52. Villunger A, Michalak EM, Coultas L *et al.* p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. *Science* 2003; 302: 1036-1038.

53. Ma Y, Conforti R, Aymeric L *et al.* How to improve the immunogenicity of chemotherapy and radiotherapy. *Cancer Metastasis Rev.* 2011; 30: 71-82.
54. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: present and future challenges. *Expert.Opin.Ther.Targets.* 2007; 11: 1299-1314.
55. Oberst A, Green DR. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. *Nature Reviews Molecular Cell Biology* 2011; 12: 757-763.

## Figure legends

### **Figure 1. Ability of TAT-RasGAP<sub>317-326</sub> to sensitize tumor cells to various cell death stimuli**

**A.** U2OS, HeLa and HCT116 were subjected to UV-C illumination or treated during 24 hours with various apoptotic stimuli as indicated in the figure. Cells were then fixed and apoptosis was counted by scoring pycnotic nuclei. C: 30  $\mu$ M cisplatin; P: 20  $\mu$ M TAT-RasGAP<sub>317-326</sub>; TAT: 20  $\mu$ M; UV-C: 15 J/m<sup>2</sup> (U2OS), 25 J/m<sup>2</sup> (HCT116 and HeLa); S: starvation; CHX: 10  $\mu$ g/ml cycloheximide; TNF $\alpha$ : 1 ng/ml (U2OS and HeLa), 0.5 ng/ml (HCT116). The results correspond to the mean  $\pm$  95% CI of independent experiments. The asterisks indicate a statistically significant difference between cells treated or not with TAT-RasGAP<sub>317-326</sub> in the presence of the apoptogenic stimuli. **B.** HeLa cells overexpressing Bcl-X<sub>L</sub> or not were treated during 24 hours with 20  $\mu$ M TAT-RasGAP<sub>317-326</sub> (P), 200 ng/mL TRAIL (TRAIL). Cells were then fixed and apoptosis was counted by scoring pycnotic nuclei. Results correspond to the mean  $\pm$  95% CI of 3 independent experiments. The asterisk denotes a statistical significant difference. **C.** HeLa cells were infected with empty virus or virus encoding Bcl-X<sub>L</sub>. Bcl-X<sub>L</sub> expression levels were assessed by Western blotting.

### **Figure 2. TAT-RasGAP<sub>317-326</sub> favors, in a caspase-independent manner, the ability of cisplatin to activate Bax**

**A.** U2OS, HeLa and HCT116 were treated for 16 hours with 20  $\mu$ M TAT-RasGAP<sub>317-326</sub> and/or with 30  $\mu$ M of cisplatin as indicated in the figure. The cells were then lysed and Bax was immunoprecipitated with an antibody (6A7) that specifically recognizes the active conformation of Bax. Western blots were revealed with the N-20 antibody recognizing all forms of Bax. IP, immunoprecipitate; TL, total lysate; \*, immunoglobulin light chains. **B.**



HeLa cells were treated during 16 hours with 20  $\mu$ M TAT-RasGAP<sub>317-326</sub> and 30  $\mu$ M cisplatin alone or in combination. Mitochondria were isolated and cross-linked with DSS. Mitochondrial proteins were extracted and Bax was analyzed by Western blotting. **C.** HCT116 were either left untreated or treated with the indicated concentrations of cisplatin for 20 hours, in the presence or in the absence of the MX1013 pan-caspase inhibitor. The cells were then lysed and the cleavage of caspase-3 was assessed by Western blotting. **D.** U2OS cells were processed as in panel A but in the presence or in the absence of 10  $\mu$ M MX1013. **E.** HeLa cells were treated for 16 hours with 20  $\mu$ M TAT-RasGAP<sub>317-326</sub> and/or with 30  $\mu$ M of cisplatin as indicated in the figure. The cells were then lysed and Bak was immunoprecipitated with an antibody (Ab-2) that specifically recognizes the active conformation of Bak. Western blots were revealed with the G23 antibody recognizing all forms of Bak. IP, immunoprecipitate; TL, total lysate; \*, immunoglobulin light chain; #, non-specific band.

### **Figure 3. TAT-RasGAP<sub>317-326</sub> does not modulate Bcl-2 family protein levels**

U2OS, HCT116 and HeLa were treated as shown in the figure for 22 hours (TAT-RasGAP<sub>317-326</sub>, 20  $\mu$ M; cisplatin, 30  $\mu$ M). Cells were then lysed and total protein extracts were immunoblotted with antibodies specific for the indicated proteins (\*: non-specific band). Note: cIAP2 was not detected in HCT116 cells.

### **Figure 4. Role of individual Bcl-2 family proteins in TAT-RasGAP<sub>317-326</sub>-mediated sensitization to cisplatin-induced apoptosis**

**A.** SV40-transformed MEFs lacking the indicated Bcl-2 family proteins were treated as indicated in the figure for 22 hours. Cells were then fixed and apoptosis was counted by scoring pycnotic nuclei. The results correspond to the mean  $\pm$  95%CI of at least three

independent experiments. The asterisks indicate a statistically significant difference (as assessed by unpaired t-test between cells treated or not with TAT-RasGAP<sub>317-326</sub> in the presence cisplatin). **B.** HeLa cells were treated for 16 hours with 20  $\mu$ M TAT-RasGAP<sub>317-326</sub> (P) and/or with 30  $\mu$ M of cisplatin (C) in the presence or in the absence of 100 nM Smac mimetic (SM) as indicated in the figure. Cells were then fixed and apoptosis was determined by scoring pycnotic nuclei. The results correspond to the mean  $\pm$  95 % CI of three independent experiments. **C.** Cells were lysed and cIAP1 and cIAP2 expression controlled by Western blotting.

**Figure 5. Puma expression per se does not render tumor cells sensitive to TAT-RasGAP<sub>317-326</sub>**

**A.** U2OS were treated with increasing concentrations of cisplatin or transfected with the indicated amounts of a Puma-encoding plasmid. Puma protein levels were then determined by quantitative Western blotting. **B.** U2OS cells were treated as in panel A and then incubated or not with TAT-RasGAP<sub>317-326</sub> (20  $\mu$ M) for 22 hours. Apoptosis was then determined. Results correspond to the mean  $\pm$  95% CI of 3 independent experiments. # indicates a statistically significant difference between cells incubated or not with TAT-RasGAP<sub>317-326</sub> at given doses of cisplatin. \$ denotes significant differences to the “0  $\mu$ M cisplatin” condition.

**Figure 6. Ectopic expression of p53 and Puma does not render cancer cells sensitive to TAT-RasGAP<sub>317-326</sub>**

U2OS were transfected with the indicated plasmids and treated or not with 20  $\mu$ M of TAT-RasGAP<sub>317-326</sub> for 22 hours. Apoptosis was then determined. Results correspond to the mean  $\pm$  95%CI of 4 independent experiments. NS, no statistically significant difference.




**Figure 7. TAT-RasGAP<sub>317-326</sub> sensitizes cancer cells to cisplatin-induced cell death irrespectively of their p53 status**

Wild-type HCT116 and p53<sup>-/-</sup> HCT116 were treated with 1 μM cisplatin in the presence or in the absence of 20 μM TAT-RasGAP<sub>317-326</sub> (P) or 20 μM TAT for 3 days. Culture medium was then replaced with fresh medium and following an additional 10-day period the number of colonies was recorded. N/T: untreated. The results correspond to the mean +/- 95% CI of at least three independent experiments. The asterisks indicate a statistically significant difference between cisplatin-treated cells incubated or not with TAT-RasGAP<sub>317-326</sub>.






**Figure 8. TAT-RasGAP<sub>317-326</sub> sensitizes HCT116 cancer cells to cisplatin-induced cell death irrespectively of their Bax and Bak status.**

**A.** Bax and Bak expression was assessed by Western blotting in wild-type (WT) HCT116, HCT116 Bak KO, HCT116 Bax KO and HCT116 Bax/Bak DKO cells (\*: non-specific band).


**B.** WT HCT116 and HCT116 Bax Bak DKO cells were treated during 24 hours with 20 μM TAT-RasGAP<sub>317-326</sub> (P), 30 μM cisplatin (C). Cells were then fixed and apoptosis was assessed by scoring pycnotic nuclei. Results correspond to the mean +/- 95% CI of 3 independent experiments. The asterisk denotes a statistical significant difference. **C.** The indicated HCT116 cell lines were treated with 2 μM cisplatin in the presence or in the absence of 20 μM TAT-RasGAP<sub>317-326</sub> (P) or 20 μM TAT for 3 days. Culture medium was then replaced with fresh medium and following an additional 10-day period the number of colonies was recorded. N/T: untreated. The results correspond to the mean +/- 95% CI of four independent experiments. The asterisks indicate a statistically significant difference between cisplatin-treated cells incubated or not with TAT-RasGAP<sub>317-326</sub>.






**Figure 1**





**Figure 2**



**Figure 3**




**Figure 4**





**Figure 5**





**Figure 6**



**Figure 7**




Figure 8